Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Rheumatoid Arthritis: Update Bulletin [December 2015]

Product Code:
Publication Date:
December 2015

Gain new KOL insights on the latest events happening in rheumatoid arthritis (RA): Topics covered include opinions regarding Lilly’s/Incyte’s baricitinib; AbbVie’s ABT 494 and Galapagos’ filgotinib; and the future usage of JAK inhibitors. Expert insight was also sought for the approval of biosimilars using extrapolated data; concerns regarding biosimilars; and AbbVie’s new formulation of Humira.

Key Questions Answered in this Update Bulletin:

  • How do KOLs view baricitinib’s Phase III clinical data results?
  • How clinically attractive are the JAK1 inhibitors ABT 494 and filgotinib?
  • How will JAK inhibitors be used in the future and what factors will impact their usage?
  • What issues do KOLs consider important regarding the approval of biosimilars?
  • What factors need to be addressed in order for biosimilars to be widely accepted?
  • Is AbbVie’s new formulation of Humira seen as exciting? Why/why not?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved